Bioventus (BVS) Net Cash Flow Growth (3y) (2023 - 2026)
Bioventus (BVS) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 269.22% |
| 10 | Bioventus | 972.56 Mn | 943.11 Mn | 105.67 Mn | 2.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 2.26% |
| Mar 28, 2026 | -42.13% |
| Dec 31, 2025 | 58.83% |
| Sep 27, 2025 | 55.32% |
| Jun 28, 2025 | 30.83% |
| Mar 29, 2025 | -5.23% |
| Dec 31, 2024 | 26.37% |
| Sep 28, 2024 | 52.24% |
| Jun 29, 2024 | -5.44% |
| Mar 30, 2024 | -31.28% |
| Dec 31, 2023 | -11.00% |
| Sep 30, 2023 | 57.02% |
| Jul 1, 2023 | -14.56% |
| Apr 1, 2023 | -36.41% |